Format

Send to

Choose Destination
J Surg Oncol. 2016 Sep;114(3):380-4. doi: 10.1002/jso.24311. Epub 2016 May 30.

Intralesional PV-10 for in-transit melanoma-A single-center experience.

Author information

1
Division of Cancer Surgery, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
2
Department of Surgery, University of Melbourne, Victoria, Australia.

Abstract

BACKGROUND AND OBJECTIVES:

Patients with in-transit melanoma metastasis have longer median survival than patients with distant metastatic disease. Furthermore, local disease control is an important endpoint for symptom management. The treatment of unresectable loco-regional recurrence or in-transit disease has been historically managed with a combination of treatments including surgery, radiotherapy, isolated limb infusion or perfusion as well as systemic therapies. Intralesional PV-10 has been used at Peter MacCallum Cancer Centre since 2010, and the current report presents a retrospective analysis of patient outcomes, reporting the response rates, durability of responses, and observed toxicities.

METHODS:

Records were analyzed retrieving details of 19 patients treated with PV-10 over a 4-year period from 2010 to 2014. Medical records were reviewed for these patients and data extracted.

RESULTS:

Nineteen patients with in-transit melanoma were treated with intralesional PV-10 between 2010 and 2014. Disease control (complete or partial response or disease stability) was achieved in 68% of patients with 26% having a complete response. This was achieved with minimal associated toxicity.

CONCLUSIONS:

PV-10 is an effective, durable, well-tolerated treatment tool with an acceptable side effect profile for the management of unresectable in-transit melanoma. J. Surg. Oncol. 2016;114:380-384. © 2016 Wiley Periodicals, Inc.

KEYWORDS:

PV-10; Rose Bengal; loco-regional; melanoma; metastasis

PMID:
27237868
DOI:
10.1002/jso.24311
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center